Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), announced a strategic partnership with LDV at The Maidstone, a historic luxury boutique hotel in East Hampton. The agreement gives Maidstone guests exclusive preferred pricing on Flyte’s private aviation services for travel to and from the Hamptons.
According to Flyte, the collaboration is intended to integrate private air travel into the overall guest experience and support its strategy to become a leading transportation partner in the Hamptons. Flyte highlights its technology-enabled booking platform, standardized pricing on select routes, and a growing fleet of Cirrus Vision Jets serving Northeast leisure destinations.
Flyte (NYSE American: VTAK), the technology-enabled Regional Air Mobility subsidiary of Catheter Precision, announced a strategic partnership with 319 Golf Society, which has members from over 70 of the top 200 U.S. private golf clubs. Flyte is named the Society’s Exclusive Private Aviation Partner.
According to the company, 319 Golf Society members receive $1,000 toward their first Flyte trip, exclusive merchandise, member gifts, and access to Flyte events and promotions. The deal targets golfers who frequently travel between private clubs, resorts, business meetings, and second homes using Flyte’s Cirrus Vision Jet fleet operated by its FAA-certified carrier Ponderosa Air.
Flyte (NYSE American: VTAK), the regional air mobility subsidiary of Catheter Precision, announced a non-exclusive strategic partnership with Blade Urban Air Mobility. Under the agreement, Flyte’s Cirrus Vision Jet fleet and charter offerings will be featured on Blade’s platform, giving Blade passengers access to Flyte’s fixed-price, technology-enabled short-haul private aviation services across the United States.
According to Flyte, the deal is expected to broaden its distribution, increase booking opportunities, and raise brand awareness among premium, time-sensitive regional travelers already using app-based air mobility. Flyte highlights its scalable operating platform, safety-focused Cirrus Vision Jet fleet, and ongoing strategy of growth through partnerships, fleet expansion, technology integration, and consumer awareness initiatives.
Flyte, the Regional Air Mobility subsidiary of Catheter Precision (NYSE American: VTAK), announced a strategic, non-exclusive partnership with Blade Urban Air Mobility to feature Flyte's Cirrus Vision Jet fleet and charter offerings on Blade's platform. Blade users will gain access to Flyte's modern, efficient regional private aviation solution, while Flyte expects increased booking opportunities, aircraft utilization, customer acquisition, and brand awareness among premium, time-sensitive travelers.
According to Flyte, this partnership supports its strategy to build a scalable regional air mobility platform through strategic partnerships, fleet expansion, technology integration, and consumer-awareness initiatives, and further validates its regional air mobility model within Blade's ecosystem.
Catheter Precision (NYSE American: VTAK) reported preliminary unaudited record revenue of $1,037,000 for the quarter ended June 30, 2026, combining its MedTech and Flyte Vision Jet segments. The Flyte Vision Jet segment generated $767,000, up 61% sequentially over Q1 2026, while the MedTech segment grew 27% over Q2 2025.
According to the company, preliminary revenue for the first two weeks of July 2026 exceeded $400,000. Catheter Precision is also working with an outside investment bank to evaluate alternative scenarios for its MedTech segment and aims to finalize related plans over the next several months.
Flyte (NYSE American: VTAK), the Regional Air Mobility arm of Catheter Precision, announced a partnership with LifeVac to place LifeVac airway clearance devices on every Cirrus Vision Jet in its fleet.
This extends Flyte’s standardized, Vision Jet–based safety ecosystem to include onboard medical emergency preparedness for choking incidents.
Catheter Precision (NYSE American: VTAK) announced issuance of two key patents covering its VIVO ventricular tachycardia mapping technology and Cardionomix heart failure neuromodulation platform.
The new European VT patent expands a portfolio of 18 VIVO-related filings, while the heart failure patent joins 33 Cardionomix patents and applications supported by early clinical data.
Flyte, a subsidiary of Catheter Precision (NYSE American:VTAK), reported approximately 170% sequential revenue growth from Q1 to Q2 2026 after launching its enhanced direct-to-consumer booking platform, flyflyte.com.
In the first half of 2026, Flyte added 1,000+ users, facilitated 118 flights, and generated over $1.0 million in revenue.
Flyte (NYSE American: VTAK), the Regional Air Mobility subsidiary of Catheter Precision, announced a partnership with talent agency GSE Worldwide and PGA TOUR professional Emiliano Grillo, debuting at the 2026 U.S. Open.
The collaboration showcases Flyte’s Cirrus Vision Jet fleet as an efficient regional travel option for elite athletes.
Volato (NYSE American: SOAR) closed a $2.2 million PIPE financing priced at $0.34 per share, issuing 6.5 million common shares. Proceeds are intended to strengthen the balance sheet and support its AI-focused aviation strategy and software-enabled operating platforms.
Strategic investors were led by Catheter Precision, parent of Flyte. The deal builds on Volato’s strategic relationship with Flyte and supports development of its AI assets, including Parslee and Volato AI, while the company evaluates potential acquisitions, mergers, and strategic combinations.